Advanced search
Publication Cover
Future Medicinal Chemistry Volume 7, 2015 - Issue 5
Submit an article Journal homepage
619
Views
0
CrossRef citations to date
0
Altmetric
Review

In Silico Prediction of hERG Inhibition

Yankang Jing1 Biogen Idec, 250 Binney Street, Cambridge, MA02142, USAView further author information
,
Alison Easter1 Biogen Idec, 250 Binney Street, Cambridge, MA02142, USAView further author information
,
David Peters1 Biogen Idec, 250 Binney Street, Cambridge, MA02142, USAView further author information
,
Norman Kim1 Biogen Idec, 250 Binney Street, Cambridge, MA02142, USAView further author information
&
Istvan J Enyedy1 Biogen Idec, 250 Binney Street, Cambridge, MA02142, USACorrespondence[email protected]
View further author information
Pages 571-586 | Published online: 29 Apr 2015

References

  • Tristani-Firouzi M , ChenJ, MitchesonJS, SanguinettiMC. Molecular biology of K+ channels and their role in cardiac arrhythmias. Am. J. Med.110 (1), 50–59 (2001).
  • Shah RR . Can pharmacogenetics help rescue drugs withdrawn from the market?Pharmacogenomics7 (6), 889–908 (2006).
  • International Conference on Harmonisation ; guidance on S7A safety pharmacology studies for human pharmaceuticals; availability. Notice. Fed. Regist.66 (135), 36791–36792 (2001).
  • International Conference on Harmonisation ; guidance on S7B nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals; availability. Notice. Fed Regist70 (202), 61133–61134 (2005).
  • International Conference on Harmonisation ; guidance on E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs; availability. Notice. Fed Regist70 (202), 61134–61135 (2005).
  • Bridgland-Taylor MH , HargreavesAC, EasterAet al. Optimization and validation of a medium-throughput electrophysiology-based hERG assay using IonWorks HT. J. Pharmacol. Toxicol. Methods54 (2), 189–199 (2006).
  • Mathes C , FriisS, FinleyM, LiuY. QPatch: the missing link between HTS and ion channel drug discovery. Comb. Chem. High Throughput Screen.12 (1), 78–95 (2009).
  • Chiu PJS , MarcoeKF, BoundsSEet al. Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels. J. Pharmacol. Sci. (Tokyo)95 (3), 311–319 (2004).
  • Chaudhary KW , O'NealJM, MoZL, FerminiB, GallavanRH, BahinskiA. Evaluation of the rubidium efflux assay for preclinical identification of hERG blockade. Assay Drug Dev. Technol.4 (1), 73–82 (2006).
  • Redfern WS , CarlssonL, DavisASet al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res.58 (1), 32–45 (2003).
  • Milan DJ , PetersonTA, RuskinJN, PetersonRT, MacRaeCA. Drugs that induce repolarization abnormalities cause bradycardia in zebrafish. Circulation107 (10), 1355–1358 (2003).
  • Aronov AM . Predictive in silico modeling for hERG channel blockers. Drug Discov. Today10 (2), 149–155 (2005).
  • Braga RC , AlvesVM, SilvaMFBet al. Tuning hERG out: antitarget QSAR models for drug development. Curr. Top. Med. Chem.14 (11), 1399–1415 (2014).
  • Wang S , LiY, XuL, LiD, HouT. Recent developments in computational prediction of hERG blockage. Curr. Top. Med. Chem.13 (11), 1317–1326 (2013).
  • Taboureau O , JorgensenFS. In silico predictions of hERG channel blockers in drug discovery: from ligand-based and target-based approaches to systems chemical biology. Comb. Chem. High Throughput Screen.14 (5), 375–387 (2011).
  • Recanatini M , CavalliA. QSAR and pharmacophores for drugs involved in hERG blockage. Methods Princ. Med. Chem.38, 109–126 (2008).
  • Verma J , KhedkarVM, CoutinhoEC. 3D-QSAR in drug design - a review. Curr. Top. Med. Chem.10 (1), 95–115 (2010).
  • Durdagi S , SubbotinaJ, Lees-MillerJ, GuoJ, DuffHJ, NoskovSY. Insights into the molecular mechanism of hERG1 channel activation and blockade by drugs. Curr. Med. Chem.17 (30), 3514–3532 (2010).
  • Keserü GM . Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. Bioorg. Med. Chem. Lett.13 (16), 2773–2775 (2003).
  • Coi A , MassarelliI, MurgiaL, SaracenoM, CalderoneV, BianucciAM. Prediction of hERG potassium channel affinity by the CODESSA approach. Bioorg. Med. Chem.14 (9), 3153–3159 (2006).
  • Song M , ClarkM. Development and Evaluation of an in silico model for hERG binding. J. Chem. Inf. Model.46 (1), 392–400 (2005).
  • Yoshida K , NiwaT. Quantitative structure-activity relationship studies on inhibition of HERG potassium channels. J. Chem. Inf. Model.46 (3), 1371–1378 (2006).
  • Kramer C , BeckB, KrieglJ, ClarkT. A composite model for hERG blockade. ChemMedChem3 (2), 254–265 (2008).
  • Garg D , GandhiT, Gopi MohanC. Exploring QSTR and toxicophore of hERG K+ channel blockers using GFA and HypoGen techniques. J. Mol. Graphics Model.26 (6), 966–976 (2008).
  • Hansen K , RathkeF, SchroeterTet al. Bias-correction of regression models: a case study on hERG inhibition. J. Chem. Inf. Model.49 (6), 1486–1496 (2009).
  • Sinha N , SenS. Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model. Eur. J. Med. Chem.46 (2), 618–630 (2011).
  • Moorthy NSH , RamosMJ, FernandesPA. Predictive QSAR models development and validation for human ether-a-go-go related gene (hERG) blockers using newer tools. J. Enzyme Inhib. Med. Chem.29 (3), 317–324 (2014).
  • Aptula AO , CroninMTD. Prediction of hERG K+ blocking potency: application of structural knowledge. SAR QSAR Environ. Res.15 (5–6), 399–411 (2004).
  • Schultz TW , CroninMTD. Essential and desirable characteristics of ecotoxicity quantitative structure-activity relationships. Environ. Toxicol. Chem.22 (3), 599–607 (2003).
  • Katritzky AR , IgnatchenkoES, BarcockRA, LobanovVS, KarelsonM. Prediction of gas chromatographic retention times and response factors using a general qualitative structure-property relationships treatment. Anal. Chem.66 (11), 1799–1807 (1994).
  • Vapnik V , ChapelleO. Bounds on error expectation for support vector machines. Neural Comput.12 (9), 2013–2036 (2000).
  • Svetnik V , LiawA, TongC, CulbersonJC, SheridanRP, FeustonBP. Random forest: a classification and regression tool for compound classification and QSAR modeling. J. Chem. Inf. Comput. Sci.43 (6), 1947–1958 (2003).
  • Pitzer EW . A review of four molecular structure indexing methods. Prepr. Am. Chem. Soc. Div. Pet. Chem.32 (2), 534–539 (1987).
  • Wermuth CG , GanellinCR, LindbergP, MitscherLA. Glossary of terms used in medicinal chemistry (IUPAC recommendations 1998). Pure Appl. Chem.70 (5), 1129–1143 (1998).
  • Ekins S , CrumbWJ, SarazanRD, WikelJH, WrightonSA. Three-dimensional quantitative structure-activity relationship for inhibition of human ether-a-go-go-related gene potassium channel. J. Pharmacol. Exp. Ther.301 (2), 427–434 (2002).
  • Morgan TK Jr , SullivanME. An overview of class III electrophysiological agents: a new generation of antiarrhythmic therapy. Prog. Med. Chem.29, 65–108 (1992).
  • Matyus P , BorosyAP, VarroA, PappJG, BarloccoD, CignarellaG. Development of pharmacophores for inhibitors of the rapid component of the cardiac delayed rectifier potassium current. Int. J. Quantum Chem.69 (1), 21–30 (1998).
  • Aronov AM , GoldmanBB. A model for identifying HERG K+ channel blockers. Bioorg. Med. Chem.12 (9), 2307–2315 (2004).
  • Aronov AM . Common pharmacophores for uncharged human ether-a-go-go-related gene (hERG) blockers. J. Med. Chem.49 (23), 6917–6921 (2006).
  • Aronov AM . Tuning out of hERG. Curr. Opin. Drug Discov. Dev.11 (1), 128–140 (2008).
  • Peukert S , BrendelJ, PirardBet al. Pharmacophore-based search, synthesis, and biological evaluation of anthranilic amides as novel blockers of the Kv1.5 channel. Bioorg. Med. Chem. Lett.14 (11), 2823–2827 (2004).
  • Durdagi S , DuffHJ, NoskovSY. Combined receptor and ligand-based approach to the universal pharmacophore model development for studies of drug blockade to the hERG1 pore domain. J. Chem. Inf. Model.51 (2), 463–474 (2011).
  • Tan Y , ChenY, YouQ, SunH, LiM. Predicting the potency of hERG K+ channel inhibition by combining 3D-QSAR pharmacophore and 2D-QSAR models. J. Mol. Model.18 (3), 1023–1036 (2012).
  • Du-Cuny L , ChenL, ZhangS. A critical assessment of combined ligand- and structure-based approaches to hERG channel blocker modeling. J. Chem. Inf. Model.51 (11), 2948–2960 (2011).
  • Kratz JM , SchusterD, EdtbauerMet al. Experimentally validated hERG pharmacophore models as cardiotoxicity prediction tools. J. Chem. Inf. Model.54 (10), 2887–2901 (2014).
  • Wolber G , LangerT. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J. Chem. Inf. Comput. Sci.45 (1), 160–169 (2005).
  • Strobl GR , von KruedenerS, StoeckigtJ, GuengerichFP, WolffT. Development of a pharmacophore for inhibition of human liver cytochrome P-450 2D6: molecular modeling and inhibition studies. J. Med. Chem.36 (9), 1136–1145 (1993).
  • Ramesh M , BharatamPV. CYP isoform specificity toward drug metabolism: analysis using common feature hypothesis. J. Mol. Model.18 (2), 709–720 (2012).
  • Güner OF , BowenJP. Pharmacophore modeling for ADME. Curr. Top. Med. Chem.13 (11), 1327–1342 (2013).
  • Cavalli A , PoluzziE, De PontiF, RecanatiniM. Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K+ channel blockers. J. Med. Chem.45 (18), 3844–3853 (2002).
  • Pearlstein RA , VazRJ, KangJet al. Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. Bioorg. Med. Chem. Lett.13 (10), 1829–1835 (2003).
  • Carosati E , LemoineH, SpogliRet al. Binding studies and GRIND/ALMOND-based 3D QSAR analysis of benzothiazine type KATP-channel openers. Bioorg. Med. Chem.13 (19), 5581–5591 (2005).
  • Ermondi G , VisentinS, CaronG. GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers. Eur. J. Med. Chem.44 (5), 1926–1932 (2009).
  • Du LP , TsaiKC, LiMY, YouQd, XiaL. The pharmacophore hypotheses of IKr potassium channel blockers: novel class III antiarrhythmic agents. Bioorg. Med. Chem. Lett.14 (18), 4771–4777 (2004).
  • Cianchetta G , LiY, KangJet al. Predictive models for hERG potassium channel blockers. Bioorg. Med. Chem. Lett.15 (15), 3637–3642 (2005).
  • Roche O , TrubeG, ZueggeJ, PflimlinP, AlanineA, SchneiderG. A virtual screening method for prediction of the hERG potassium channel liability of compound libraries. ChemBioChem3 (5), 455–459 (2002).
  • Hidaka S , YamasakiH, OhmayuYet al. Nonlinear classification of hERG channel inhibitory activity by unsupervised classification method. J. Toxicol. Sci.35 (3), 393–399 (2010).
  • Vracko M . Kohonen artificial neural network and counter propagation neural network in molecular structure-toxicity studies. Curr. Comput. Aided Drug Des.1 (1), 73–78 (2005).
  • Roche O , TrubeG, ZueggeJ, PflimlinP, AlanineA, SchneiderG. A virtual screening method for prediction of the hERG potassium channel liability of compound libraries. ChemBioChem3 (5), 455–459 (2002).
  • Bains W , BasmanA, WhiteC. HERG binding specificity and binding site structure: evidence from a fragment-based evolutionary computing SAR study. Prog. Biophys. Mol. Biol.86 (2), 205–233 (2004).
  • Tobita M , NishikawaT, NagashimaR. A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors. Bioorg. Med. Chem. Lett.15 (11), 2886–2890 (2005).
  • Dubus E , IjjaaliI, PetitetF, MichelA. In silico classification of herg channel blockers: a knowledge-based strategy. ChemMedChem1 (6), 622–630 (2006).
  • Sun H . An accurate and interpretable bayesian classification model for prediction of hERG liability. ChemMedChem1 (3), 315–322 (2006).
  • Ekins S , BalakinKV, SavchukN, IvanenkovY. Insights for human ether-a-go-go-related gene potassium channel inhibition using recursive partitioning and kohonen and sammon mapping techniques. J. Med. Chem.49 (17), 5059–5071 (2006).
  • Gepp MM , HutterMC. Determination of hERG channel blockers using a decision tree. Bioorg. Med. Chem.14 (15), 5325–5332 (2006).
  • Wang M , YangXG, XueY. Identifying hERG potassium channel inhibitors by machine learning methods. QSAR Comb. Sci.27 (8), 1028–1035 (2008).
  • Thai KM , EckerGF. A binary QSAR model for classification of hERG potassium channel blockers. Bioorg. Med. Chem.16 (7), 4107–4119 (2008).
  • Jia L , SunH. Support vector machines classification of hERG liabilities based on atom types. Bioorg. Med. Chem.16 (11), 6252–6260 (2008).
  • Li Q , JorgensenFS, OpreaT, BrunakS, TaboureauO. hERG classification model based on a combination of support vector machine method and GRIND descriptors. Mol. Pharmaceutics5 (1), 117–127 (2008).
  • Chekmarev DS , KholodovychV, BalakinKV, IvanenkovY, EkinsS, WelshWJ. Shape signatures: new descriptors for predicting cardiotoxicity in silico. Chem. Res. Toxicol.21 (6), 1304–1314 (2008).
  • Filz O , LaguninA, FilimonovD, PoroikovV. Computer-aided prediction of QT-prolongation. SAR QSAR Environ. Res.19 (1–2), 81–90 (2008).
  • Thai KM , EckerGF. Similarity-based SIBAR descriptors for classification of chemically diverse hERG blockers. Mol. Diversity13 (3), 321–336 (2009).
  • Nisius B , GöllerAH. Similarity-based classifier using topomers to provide a knowledge base for hERG channel inhibition. J. Chem. Inf. Model.49 (2), 247–256 (2009).
  • Su BH , ShenMy, EspositoEX, HopfingerAJ, TsengYJ. In silico binary classification QSAR models based on 4D-fingerprints and MOE descriptors for prediction of hERG blockage. J. Chem. Inf. Model.50 (7), 1304–1318 (2010).
  • Doddareddy MR , KlaasseEC, Shagufta, IJzermanAP, BenderA. Prospective validation of a comprehensive in silico herg model and its applications to commercial compound and drug databases. ChemMedChem5 (5), 716–729 (2010).
  • Wang S , LiY, WangJet al. ADMET evaluation in drug discovery. 12. Development of binary classification models for prediction of herg potassium channel blockage. Mol. Pharmaceutics9 (4), 996–1010 (2012).
  • Broccatelli F , MannholdR, MoriconiA, GiuliS, CarosatiE. QSAR modeling and data mining link torsades de pointes risk to the interplay of extent of metabolism, active transport, and hERG liability. Mol. Pharmaceutics9 (8), 2290–2301 (2012).
  • Su BH , TuYs, EspositoEX, TsengYJ. Predictive toxicology modeling: protocols for exploring hERG classification and tetrahymena pyriformis end point predictions. J. Chem. Inf. Model.52 (6), 1660–1673 (2012).
  • Czodrowski P . hERG me out. J. Chem. Inf. Model.53 (9), 2240–2251 (2013).
  • Labute P . A widely applicable set of descriptors. J. Mol. Graphics Model.18 (4/5), 464–477 (2000).
  • Cherkasov A . ‘Inductive’ descriptors: 10 successful years in QSAR. Curr. Comput. Aided Drug Des.1 (1), 21–42 (2005).
  • Güner OF , HenryDR. Formula for determining the “goodness of hit lists” in 3D database searches. Network Sci.4 (6), (1998).
  • Cruciani G , CrivoriP, CarruptPA, TestaB. Molecular fields in quantitative structure-permeation relationships: the VolSurf approach. J. Mol. Struct. (Theochem)503 (1–2), 17–30 (2000).
  • Oesterberg F , AqvistJ. Exploring blocker binding to a homology model of the open hERG K+ channel using docking and molecular dynamics methods. FEBS Lett.579 (13), 2939–2944 (2005).
  • Stansfeld PJ , GedeckP, GoslingM, CoxB, MitchesonJS, SutcliffeMJ. Drug block of the hERG potassium channel: insight from modeling. Proteins: Struct. Funct. Bioinf.68 (2), 568–580 (2007).
  • Subbotina J , Yarov-YarovoyV, Lees-MillerJet al. Structural refinement of the hERG1 pore and voltage-sensing domains with ROSETTA-membrane and molecular dynamics simulations. Proteins: Struct. Funct. Bioinf.78 (14), 2922–2934 (2010).
  • Farid R , DayT, FriesnerRA, PearlsteinRA. New insights about HERG blockade obtained from protein modeling, potential energy mapping, and docking studies. Bioorg. Med. Chem.14 (9), 3160–3173 (2006).
  • Masetti M , CavalliA, RecanatiniM. Modeling the hERG potassium channel in a phospholipid bilayer: molecular dynamics and drug docking studies. J. Comput. Chem.29 (5), 795–808 (2008).
  • Stary A , WackerSJ, BoukhartaLet al. Toward a consensus model of the hERG potassium channel. ChemMedChem5 (3), 455–467 (2010).
  • Moroy G , MartinyVY, VayerP, VilloutreixBO, MitevaMA. Toward in silico structure-based ADMET prediction in drug discovery. Drug Discov. Today17 (1–2), 44–55 (2012).
  • Doyle DA , CabralJM, PfuetznerRAet al. The structure of the potassium channel: molecular basis of K+ conduction and selectivity. Science280 (5360), 69–77 (1998).
  • Jiang Y , LeeA, ChenJet al. X-ray structure of a voltage-dependent K+ channel. Nature423 (6935), 33–41 (2003).
  • Jiang Y , LeeA, ChenJ, CadeneM, ChaitBT, MacKinnonR. Crystal structure and mechanism of a calcium-gated potassium channel. Nature417 (6888), 515–522 (2002).
  • Long SB , CampbellEB, MacKinnonR. Crystal structure of a mammalian voltage-dependent shaker family K+ channel. Science309 (5736), 897–903 (2005).
  • Berman HM , WestbrookJ, FengZet al. The protein databank. Nucleic Acids Res.8 (1), 235–242 (2000).
  • Tristani-Firouzi M , SanguinettiMC. Structural determinants and biophysical properties of HERG and KCNQ1 channel gating. J. Mol. Cell. Cardiol.35 (1), 27–35 (2003).
  • Yi H , CaoZ, YinS, DaiC, WuY, LiW. Interaction simulation of hERG K+ channel with its specific BeKm-1 peptide: insights into the selectivity of molecular recognition. J. Proteome Res.6 (2), 611–620 (2007).
  • Imai YN , RyuS, OikiS. Docking model of drug binding to the human ether-a-go-go potassium channel guided by tandem dimer mutant patch-clamp data: a synergic approach. J. Med. Chem.52 (6), 1630–1638 (2009).
  • Du L , LiM, YouQ, XiaL. A novel structure-based virtual screening model for the hERG channel blockers. Biochem. Biophys. Res. Commun.355 (4), 889–894 (2007).
  • Durdagi S , DeshpandeS, DuffHJ, NoskovSY. Modeling of open, closed, and open-inactivated states of the hERG1 channel: structural mechanisms of the state-dependent drug binding. J. Chem. Inf. Model.52 (10), 2760–2774 (2012).
  • Dempsey CE , WrightD, ColensoCK, SessionsRB, HancoxJC. Assessing hERG pore models as templates for drug docking using published experimental constraints: the inactivated state in the context of drug block. J. Chem. Inf. Model.54 (2), 601–612 (2014).
  • Schmidtke P , CiantarM, TheretI, DucrotP. Dynamics of hERG closure allow novel insights into hERG blocking by small molecules. J. Chem. Inf. Model.54 (8), 2320–2333 (2014).
  • Dixon SL , SmondyrevAM, KnollEH, RaoSN, ShawDE, FriesnerRA. PHASE: A New Engine for Pharmacophore Perception, 3D QSAR Model Development, and3D Database Screening. 1. Methodology and Preliminary Results. J. Comput. Aided Mol. Des.20, 647–671 (2006).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.